Literature DB >> 26908331

Expression of the innate immune receptor LILRB5 on monocytes is associated with mycobacteria exposure.

Louise E Hogan1,2, Des C Jones3, Rachel L Allen1.   

Abstract

Antigen presenting cells (APC) are critical components of innate immunity and consequently shape the adaptive response. Leukocyte Ig Like Receptors (LILR) are innate immune receptors predominantly expressed on myeloid cells. LILR can influence the antigen presenting phenotype of monocytic cells to determine the nature of T cell responses in infections including Mycobaterium leprae. We therefore investigated the relevance of LILR in the context of Mycobacterium tuberculosis. Real-time PCR studies indicated that the transcriptional profile of the orphan receptor LILRB5 was significantly up-regulated following exposure to mycobacteria. Furthermore, LILRA1 and LILRB5 were able to trigger signalling through direct engagement of mycobacteria using tranfectant cells incorporating a reporter system. We describe for the first time the expression of this receptor on T cells, and highlight the potential relevance to mycobacterial recognition. Furthermore, we demonstrate that crosslinking of this receptor on T cells increases proliferation of cytotoxic, but not helper, T cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26908331      PMCID: PMC4764857          DOI: 10.1038/srep21780

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Leukocyte immunoglobulin-like receptors (LILR) are a group of receptors with activating or inhibitory functions, that are expressed on the surface of myelomonocytic cells, including antigen presenting cell subsets. In addition to their classification as activatory (LILRA1-2, 4–6) or inhibitory (LILRB1-5) on the basis of signalling motifs, LILR are designated as group I or group II on the basis on their predicted ability to bind MHC class I (MHC-I)12. Through their expression on monocytic cells LILR have been shown to regulate TLR activity3456789, antigen presenting phenotype10111213 and cytokine secretion profile71415, thus demonstrating the potential to influence subsequent immune responses4161718. Variations in the strength of binding of LILRB2 to different HLA alleles expressed by HIV infected patients was recently shown to correlate with control of infection19. In Mycobacterium leprae (M. Leprae) infection, LILR are thought to be responsible for influencing the immune response and their expression profile has been shown to correlate with disease phenotype. Comparison of lepromatous and tuberculoid leprosy samples showed increased expression of LILRA2 in the skin lesions of patients with lepromatous leprosy, a disease profile associated with disseminated disease and ineffective bacilli clearance resulting from a Th2 biased response. This is in contrast to tuberculoid leprosy, in which a strong Th1 biased response enables the effective clearance of bacilli from localised infection. Crosslinking of LILRA2 on macrophages resulted in a 40% reduction in intracellular killing of mycobacteria, indicating that LILRA2 may inhibit anti-microbial functions in macrophages. The ligation of LILRA2 also considerably reduced the induction of IL-12 production by TLRs, skewing cytokine activity towards a Th2 biased response420. As there is evidence for LILR-mediated modulation of immune responses during M. leprae infection, it is possible that the expression and functions of these receptors are relevant during infection with other mycobacteria such as Mycobacterium tuberculosis (M. tb). In support of this, the up-regulation of HLA-G, the highest affinity self-ligand for LILRB1 and LILRB2, has been documented by both gene expression assays21 and surface expression analysis of macrophages from patients with M. tb22. LILRB1 expression on NK cells correlates with disease severity in pulmonary tuberculosis23, while expression on CD4 T cells, together with CD152 has been proposed to regulate cytolytic activity24. Furthermore, TLR2/1/6 heterodimers, TLR4, TLR8, and TLR9 and are implicated in the initial recognition of M.tb, and the regulation of these receptors may contribute to down-stream responses2526272829. We therefore decided to investigate the potential role of LILR in the context of M. tb infection. Tuberculosis per se, primarily results from infection with the organism M. tb, but there have been documented cases indicating Mycobacterium bovis (M. bovis) as a causative agent3031. Furthermore, the attenuated strain of M. bovis used in vaccinations, Bacillus Calmette-Guérin (BCG), causes disease in immunocompromised individuals32. We therefore hypothesized that LILR responses may vary between mycobacterial species. Furthermore, non-specific protection arising from various live vaccinations is thought to develop through epigenetic changes in the innate immune environment33. This led us to consider that prior BCG vaccination may exert a relevant effect on monocytic cell phenotype. To elucidate the mechanisms involved, we sought to compare LILR expression profiles for antigen presenting cells (APC) exposed to M. tb, M. bovis, and BCG comparing cells from BCG vaccinated and unvaccinated donors. LILR can interact directly with bacteria, specifically, LILRB1 and LILRB3 have been shown to bind bacteria including E. coli, H. pylori and S. aureus34 with individual receptors varying in their bacterial specificity. The bacterial ligand(s) involved in this interaction are yet to be determined in full, although lipoteichoic acid on S. aureus has been suggested as one potential ligand35. Therefore, it is also possible that LILR may directly interact with one or more mycobacterial ligands. As LILR regulate TLR activity, any potential interaction with mycobacterial antigens could have a distinct impact on the resulting immune response. Here, we describe variations in LILR profile between APC derived from BCG vaccinated and unvaccinated individuals, which indicate that BCG vaccination decreases the expression of LILRA3 and LILRB2 on monocyte-derived macrophages. Moreover, LILRB5 is up-regulated in monocyte-derived DC in response to mycobacterial species, significantly so after BCG exposure. Furthermore, BCG elicits LILRA1 and LILRB5 signalling in a reporter system. Finally, we describe for the first time LILRB5 expression on T cells, and demonstrate that ligation of LILRB5 on T cells induces CD8, but not CD4, T cell proliferation.

Results

Comparison of LILR expression profiles for BCG vaccinated and unvaccinated donors

To date, LILR expression profile studies have been hindered by a lack of specific monoclonal antibodies for each member of the receptor family. As such, we analysed the 11 human LILR using a Real-Time PCR assay. Distinct mRNA profiles of LILR expression were observed for both in vitro monocyte-derived macrophages (MDM) and monocyte-derived DC (moDC) from BCG vaccinated vs. unvaccinated donors (Fig. 1). Statistically significant differences were seen for two of the eleven LILR in MDM. Most strikingly, LILRA3, the only LILR to lack any transmembrane or cytoplasmic domain, had significantly (p = 0.027) lower expression on MDM samples from BCG vaccinated donors compared with unvaccinated donors. LILRB2 was also expressed at lower levels by MDM from vaccinated donors (p = 0.025). As both of these receptors are known to have inhibitory functions, this may be a potentially beneficial finding in the presence of mycobacterial infection.
Figure 1

Expression of LILR encoding transcripts in moDC and MDM samples derived from BCG vaccinated and unvaccinated donors, as determined using qPCR analysis.

The y axis denotes Ct value, which is relative to GAPDH expression. Mann-Whitney analysis demonstrated a significant difference (p < 0.05) in MDM expression of LILRA3 (p = 0.027) and LILRB2 (p = 0.025) between samples derived from BCG vaccinated and unvaccinated donors. The number of paired samples used for each condition is depicted in Table 1.

BCG vaccination affects LILR expression profiles in the presence of mycobacteria

LILR mRNA expression profiles were then compared for moDC and MDM following in vitro culture with BCG, M. bovis and M. tb (H37Rv). Donors were grouped based on their BCG vaccination status. In dendritic cell cultures, LILRA3 was down-regulated following culture with all three organisms for moDC derived from unvaccinated donors; however, this down-regulation was only significant following M. bovis exposure (p = 0.028) (Fig. 2). These effects were not detected for moDC derived from BCG vaccinated donors. The most striking results were seen for LILRB5, in which moDC derived from BCG vaccinated donors up-regulated LILRB5 following exposure to all three mycobacteria, significantly so following culture with BCG (p = 0.034). These changes in expression were not observed for moDC derived from unvaccinated donors.
Figure 2

Expression of LILR encoding transcripts in moDC samples derived from BCG vaccinated and unvaccinated donors, cultured with various mycobacterial species, as determined using qPCR analysis.

The y axis denotes Ct value, which is relative to GAPDH expression. Mann-Whitney analysis demonstrated a significant difference in moDC expression of LILRA3 between untreated and M. bovis treated samples from unvaccinated donors (p = 0.028). Furthermore, LILRB5 demonstrated significant differences between untreated and BCG treated samples from BCG vaccinated donors (p0.034), and M. bovis and H37Rv treated samples also from BCG vaccinated donors (p = 0.041). The number of paired samples used for each condition is depicted in Table 1.

For macrophage cultures, LILRA3 was again down-regulated following exposure to M. bovis and H37RV, significantly so for M. bovis (p = 0.047) in BCG unvaccinated donors (Fig. 3). Furthermore, following culture with BCG and H37Rv, MDM derived from BCG vaccinated donors expressed significantly less LILRA3 compared to their unvaccinated counterparts (BCG: p = 0.047, H37Rv: p = 0.047). LILRB2 was also found to be expressed in significantly higher levels following H37Rv culture on MDM derived from unvaccinated donors, than their BCG vaccinated counterparts (P = 0.028).
Figure 3

Expression of LILR encoding transcripts in MDM samples derived from BCG vaccinated and unvaccinated donors, cultured with various mycobacterial species, as determined using qPCR analysis.

The y axis denotes Ct value, which is relative to GAPDH expression. Mann-Whitney analysis demonstrated a significant difference in MDM expression of LILRA3 between untreated and M. bovis treated samples from unvaccinated donors (p = 0.047), and between BCG vaccinated and unvaccinated donors in untreated (p = 0.027), BCG treated (p = 0.047) and H37Rv treated (p = 0.047) samples. Furthermore, LILRB2 demonstrated significant differences between untreated and M. bovis treated samples from unvaccinated donors (p0.016), and between BCG vaccinated and unvaccinated donors in untreated (p = 0.025) and H37Rv treated samples (p = 0.028).

It is interesting to note that LILRB5 is the only receptor up-regulated in response to mycobacterial exposure, which may indicate a more distinct role for this receptor in M. tb infection. In order to examine the potential relevance of this we proceeded to examine direct binding within a reporter system.

BCG elicits LILRA1 and LILRB5 signalling in a reporter system

Binding of whole bacteria by individual LILR and PIR has been demonstrated in previous studies3435 with lipoteichoic acid suggested as a potential bacterial ligand for these receptors35. It is therefore possible that a subset of LILR could engage components of M. tb, M. bovis or BCG through a similar process. To determine whether any members of the LILR family may be capable of direct interaction with mycobacteria, a panel of 2B4 reporter cell lines each expressing an NFAT-GFP (Nuclear Factor of Activated T cell–Green Fluorescent Protein) reporter construct and a LILR-CD3ζ construct were used. As 2B4 is a T cell hybridoma cell line, it would not be expected to internalise mycobacteria. Signalling transfectants of LILRA1, LILRA2, LILRB1, LILRB3, LILRB5 and LILR-negative controls were used to determine whether signalling was induced in the presence of M. bovis (heat-killed), M. tb (heat-killed) and BCG (live). No equivalent transfectants of LILRA3, LILRA4, LILRA5, LILRA6, LILRB2 or LILRB4 were used (Fig. 4).
Figure 4

Engagement of mycobacteria by transfected LILR.

Detection of GFP production resulting from engagement of LILR with M. tb, M. bovis or BCG. These are representative results from n = 3 experiments, from which all data was consistent.

The results indicate that BCG can interact with both LILRA1 and LILRB5 to induce signalling through the CD3ζ construct in this system. A slight shift in fluorescence was detectable for LILRA1 transfectants incubated with M. bovis, which may indicate a weak interaction. None of the transfected LILR could interact with the H37Rv strain of M. tb. Given the difference in results observed between heat-killed M. bovis and live BCG, the effect of heat killing on receptor binding was assessed using BCG. To achieve this, BCG was grown to exponential phase and heat killed prior to incubation with the signalling transfectant lines, and the results were compared with live BCG (Fig. 5). LILRB1 and LILRB3 transfectant lines were used as negative controls for this experiment due to their lack of interaction with live BCG. The results demonstrate that heat killing of mycobacteria may reduce receptor binding and consequent signalling, as evidenced by the reduced signalling observed for LILRB5 incubated with heat killed mycobacteria. Thus, the reduction in binding seen after heat killing may indicate that the ligand(s) is not heat stable.
Figure 5

Engagement of BCG and heat killed BCG by transfected LILR.

Detection of GFP production resulting from engagement of LILR with heat killed BCG, and compared to live BCG from Fig. 4. These are representative results from n = 3 experiments, from which all data was consistent.

LILRB5 is expressed on T cells

To date, characterisation of LILRB5 and its functions are unclear. One investigation identified LILRB5 mRNA in NK cells36. In order to investigate LILRB5 surface expression more thoroughly, a commercially available LILRB5-specific antibody was used to determine the expression of LILRB5 on PBMC. A whole blood flow cytometry method was followed to analyse immune cell subsets including monocytes, pDC, mDC, NK, NKT, CD4+ T cells, CD8+ T cells and γδ T cells on cells derived from healthy controls who had received BCG vaccination (Fig. 6).
Figure 6

Expression summary of LILRB5 staining on immune cell subsets.

This figure depicts the median percentage of each immune cell subset that stained positive for LILRB5 (n = 3), and the corresponding MFI.

In agreement with the mRNA expression data described above, LILRB5 was expressed at very low levels on monocytes and DC. However, LILRB5 was found to be predominantly expressed on T cells (Fig. 7), and on a small percentage of γδ T cells. To confirm this data, we analysed the mRNA levels of LILRB5 for T cells isolated by magnetic separation (Fig. 8).
Figure 7

Surface expression of LILRB5 on CD4 and CD8 T cells.

The secondary antibody alone was used as a control for non-specific binding. The results show the binding for three individual donors.

Figure 8

Expression of LILR encoding transcripts in T cell populations.

LILRB5 amplification is represented in red, and GAPDH amplification is represented in green. LILRB5 was detected in magnetically isolated T cells from BCG vaccinated donors, using qPCR. This is a representative result from n = 5 samples, of which all data was consistent.

While we anticipated LILRB5 expression to be predominantly on antigen presenting cells (APC), with its expression on T cells somewhat unusual, LILRB1 is also known to be expressed on T cells, and thus such a precedent exists37.

LILRB5 ligation increases proliferation of cytotoxic, but not helper, T cells

Individual receptors in the LILR family exert functional effects that vary between cell types. The majority of studies to date have focussed on the effects of LILR activity on antigen presenting functions of monocytic cells13. Given the unexpected expression of LILRB5 on T cells, we investigated the potential functions of LILRB5 by crosslinking this receptor and analysing the effects using an allogeneic mixed lymphocyte reaction (Fig. 9).
Figure 9

Allogeneic mixed lymphocyte reaction.

Isolated CD4 of CD8 T cells, or APC, were treated with crosslinking LILRB5 antibody, and the resulting proliferation measured using flow cytometry. Crosslinking LILRB5 on CD8 T cells was found to significantly increase proliferation (p = 0.0049), as compared to the secondary antibody alone, using a two-tailed paired t test. This effect was not observed for CD4 T cells. The above data represents n = 4 BCG vaccinated donors.

Crosslinking of LILRB5 was achieved using a mouse anti-human IgG secondary antibody. However as our data shows, the secondary antibody alone consistently reduced CD8 T cell proliferation. Nonetheless, LILRB5 was able to overcome this effect, and increase proliferation when compared to the anti-IgG secondary antibody alone. Specifically, whereas APC pre-treated with LILRB5 antibody resulted a slight increase in T cell proliferation, pre-treatment of CD8 T cells produced a significant increase in proliferation compared to the secondary antibody alone (p = 0.0049). This was not found in CD4 T cell proliferation, demonstrating that, at least for cytotoxic T cells, LILRB5 ligation enhances proliferation. While the functional relevance of increasing T cell proliferation through LILRB5 signalling needs to be further characterised before any conclusions can be drawn, cytotoxic T cells are a fundamental component of anti-mycobacterial responses, and unless functionally altered, increased proliferation may be a beneficial factor.

Discussion

With a growing body of evidence to support the existence of ‘innate imprinting’ or ‘trained immunity’, new light is being shed on the long term effects of vaccinations, and the ways in which they might shape immune responses. Several studies have demonstrated the ability of certain proteins to permanently alter APC phenotype38, and BCG vaccination has been shown to increase the expression of activation markers and production of pro-inflammatory cytokines in monocytes through epigenetic reprogramming3339. Therefore, before analysing the effects of mycobacterial infection on LILR expression, APC derived from BCG-vaccinated donors were compared with those from unvaccinated donors in order to identify any pre-existing differences in LILR expression. While no differences were observed for moDC between the two groups, two LILR were found to differ in expression levels for MDM. LILRA3, the only member of the family to be genomically encoded as a soluble protein, was expressed at significantly lower levels in MDM from BCG vaccinated donors compared to unvaccinated donors. Similarly for LILRB2, a significantly lower expression was also observed for MDM derived from BCG vaccinated donors compared to MDM derived from unvaccinated donors. It is interesting to note that although LILRA3 is designated as an activating receptor for the purposes of nomenclature, the functional effects of this receptor are thought to be inhibitory. This protein can only be expressed in soluble form, and soluble LILR are thought to antagonise the functions of their cell surface counterparts by blocking ligand recognition40. LILRA3 is thought to inhibit the interactions of the activating receptor LILRA1 in this manner41. Thus, our findings indicate that BCG vaccination leads to the down-regulation of two receptors with inhibitory functions, which may be a potentially beneficial response in the presence of mycobacteria. Of all the changes detected in LILR mRNA expression, LILRB5 was the only receptor to be significantly up-regulated in response to mycobacterial challenge. In moDC, up-regulation of LILRB5 expression was exclusively seen in cells derived from BCG vaccinated donors, following exposure to mycobacteria. In MDM, only exposure to M. bovis elicited this up-regulation, which was again, only seen in cells derived from vaccinated donors. Finding LILRB5 upregulated following exposure to mycobacterium species led us to hypothesise that this receptor may have a more pertinent role in infection. By incorporating a reporter system, we analysed the ability of the mycobacterial species to trigger signalling via direct engagement of transfectant cells. Our results demonstrated signalling from LILRA1 and LILRB5, indicating again a potential role for LILBR5 during infection. Furthermore, as LILRA3 is thought to inhibit LILRA1 through competitive inhibition36, it is interesting to note that BCG vaccination appears to reduce LILRA3 expression, possibly resulting in less inhibition of LILRA1 binding in the presence of mycoabcterial infection. Members of the LILR family and their murine orthologyes have previously been shown to bind S.aureus and E.coli34, and lipoteichoic acid has been identified as a putative bacterial ligand for the murine PIR-B receptor35. It is therefore possible to speculate that lipoteichoic acid may also be a ligand for LILRB5. However, lipoteichoic acid is heat stable42 and therefore its binding would not be expected to be lost following heat treatment as seen in our assays. The M. tb cell wall primarily contains mycolic acid, lipomannan, and lipoarabinomannan lipids, but these components have also been shown to be very heat stable, contributing to the robustness of this bacterium. Nonetheless, TLR-4 was shown to bind a heat-labile antigen which was referred to as ‘heat-sensitive, cell-associated factor’26. Further studies will be necessary to identify a mycobacterial ligand for LILRB5. With limited published information to describe the protein expression profile, ligand specificity and function of LILRB5, it is difficult to predict whether changes in LILRB5 expression on APC might be detrimental to eliciting an effective immune response. However, LILRA3 together with LILRB5 and LILRB3 were found to be over expressed in lesions of patients with lepromatous leprosy, where their overexpression was thought to correspond to an ineffective immune response43. If these receptors do decrease the efficiency of immune responses it would raise the question of whether BCG vaccination does in fact prime APC in an appropriate way to generate a robust T cell response to mycobacterial infection. LILRB5 mRNA was previously found to be expressed by NK cells36, while the protein has been described on the surface of osteoclasts40 and secreted by mast cells44. Other studies have documented LILRB5 up-regulation under certain conditions in adipose tissue45, PBMC following IFN treatment of MS46, TNF treated DC47, and malignant pleural mesothelioma48. LILRB5 protein was identified in an intracellular compartment of mast cells, where although it has been shown to mobilize as a result of crosslinking FcεRI, its functions remain elusive44. In an attempt to further characterise this receptor, we analysed the surface expression of LILRB5 on immune subsets, using a recently available anti-LILRB5 antibody. LILRB5 was expressed by more than 80% of CD4 and CD8 T cells, and on a proportion of γδ T cells. As regulators of TLR, the role of LILR on T cells may be similar to that on APC. Whereas ligation of TLR expressed on APC results in cellular activation and maturation, TLR expression on T cells is thought to provide co-stimulatory signals during T cell activation, and promote proliferation and survival in effector cells495051. TLR2 has also been shown to lower the activation threshold of CD8 T cells in mice52. We examined the effect of cross-linking LILRB5 in an allogeneic mixed lymphocyte reaction. Pre-treatment with LILRB5 ligation significantly increased proliferation of CD8 but not CD4 T cells. It is not unusual for LILR to have differing functions depending on the type of cell they are expressed on, and therefore, whilst we can conclude that one function of LILRB5 may be to increase proliferation of cytotoxic T cells, the expression of LILRB5 on helper T cells is not associated with either promoting or inhibiting proliferation. These data would support the notion that LILRB5 expression on cytotoxic T cells may mediate the threshold of activation. In conclusion, this study provides evidence that LILR expression and functions are affected by exposure to M. bovis and its attenuated strain BCG. LILRB5 is both able to engage our transfectant cells, and is up-regulated following exposure to M. Bovis. Further investigation revealed this receptor to be expressed predominantly on T cells, and able to enhance cytotoxic T cell proliferation. The presence of LILRB5 on T cells and its apparent ability to bind M. bovis warrants further investigation as to whether and how this receptor can influence the immune response during mycobacterial infection.

Materials and Methods

Human Study Populations

Ethical approval for this study was granted by London and Surrey Borders Research Ethics Committee on 24th May 2010, ref. 10/H0806/41, and this study was carried out in accordance with the approved guidelines. Healthy participants were recruited from St George’s, University of London, and were not selected with regard to age, sex or ethnic origin, but were asked to provide BCG vaccination details. Informed consent was obtained from all participants prior to collection of 50 ml blood samples.

Culture of in vitro-derived macrophages and dendritic cells

Peripheral blood mononuclear cells were separated using density centrifugation over Ficoll-paque (GE Healthcare, UK). Adherent cells were cultured in RPMI1640 containing 1% autologous plasma, 1% Penicillin/Streptomycin (Sigma, UK). Monocyte derived macrophages (MDM) were differentiated in 50 ng/ml M-CSF (Peprotech, UK) and monocyte derived dendritic cells (moDC) in 50 ng/ml IL-4 and GM-CSF (Peprotech, UK). Cytokines were replenished every 48 hours. After six days, 0.5 ng/ml bacterial lipopolysaccharide (LPS) (Sigma, UK) was added to mature the cells.

Culture of BCG, M. tuberculosis and M. bovis

Thawed aliquots of BCG, M. tuberculosis (H37Rv) and M. bovis (AF2122/97) were used to initiate cultures. Original mycobacterial aliquots were kindly provided by Prof P. Butcher (St George’s, University of London, UK) and Prof M. Vordermeier (APHA, UK). Each aliquot was cultured at 37 °C for ten days in 10mls of 7H9 broth (Difco Laboratories, UK) supplemented with 0.5% glycerol (BCG, M. tuberculosis (Sigma, UK)) or 0.5% sodium pyruvate (M. bovis (Invitrogen, UK)), followed by a further ten days in 100 mls of supplemented broth at 37 °C. Colony forming units (CFU) were assessed using 10-fold serial dilutions on 7H11 agar plates (Difco Laboratories, UK). The culture was aliquoted and frozen at −80 °C until use.

Infection of moDC and MDM with BCG, M. tuberculosis or M. bovis

Antibiotic-free RPMI was used for culture of cells in infection studies. Mycobacteria in the exponential phase of growth were added to cells at a multiplicity of infection (MOI) of 10:1 (M. tuberculosis:cells) and incubated at 37 °C for 24 hours. The cells were then washed gently three times with PBS to remove excess bacteria.

RNA extraction and cDNA synthesis

RNA extraction and cDNA synthesis were performed as previously described40. Briefly, RNA was extracted from moDC and MDM using an RNeasy Kit (Qiagen, UK) following the manufacturers standard protocol. RNA was eluted in 40 μl of 0.2 μm sterile filtered H2O (Sigma, UK), and underwent a second DNase treatment using a Turbo DNase Free kit (Ambion, USA). Genomic DNA contamination was assessed by quantitative PCR (qPCR) using a GAPDH reaction. cDNA synthesis was performed using Superscript III with an Oligo(dT)20 primer (Invitrogen, UK) at 50 °C for 1 hour, following the manufacturer’s standard protocol.

Real-Time Quantitative PCR (qPCR)

qPCR was employed to determine the relative levels of all 11 LILR transcripts in moDC and MDM. PCR primers to detect the full-length, membrane-associated protein encoding LILR transcripts were supplied by Sigma (Sigma, UK)40. Primer pairs, including the oligonucleotide sequences and their final working concentration were used as previously described40. For normalisation, reactions were also used to determine the expression of the reference gene GAPDH. QPCR reactions consisted of 10 μl of 2× QuantiTect SYBR Green solution (Qiagen, UK), 1 ng cDNA, 2x oligonucleotides and brought to a final volume of 20 μl with 0.2 μm filtered H2O (Sigma, UK). Each sample was run in triplicate, with an accompanying non-template RNA control run in duplicate for every sample. GAPDH reference targets were also run for each sample in order to normalise the results. qPCR was performed on the Stratagene Mx3005 Pro PCR analyser (Stratagene, UK), or the Bio-Rad CFX96 real-time detection system (BioRad, UK). The cycling parameters were as follows: 95 °C for 15 minutes, followed by 50 cycles of 94 °C for 15 s, 60 °C for 30 s and finally 72 °C for 30 s, after which the fluorescence levels of both SYBR Green and the reference dye ROX were acquired. Baselines and thresholds were automatically calculated for all reactions on all runs using the Stratagene MxPro or CFX manager software. Finally, the standard dissociation reaction was performed between 60 °C and 95 °C in order to assess the integrity of the PCR products. Results were exported into qBasePLUS53 to perform the following analyses: After calculating the average amplification efficiency (E) of each reaction (as assessed from three independent serial dilutions) using linear regression, the relative expression level of each target transcript in each sample was normalised against the reference gene GAPDH, and then the inter-plate calibrators were used to correct any inter-plate variability. Finally, the results were exported to GraphPad Prism to perform statistical analysis. Sample numbers for each analysis are shown in Table 1.
Table 1

Number of donors included in each RT-PCR experiment.

 Samples derived from BCG Vaccinated donorsSamples derived from Unvaccinated donors
moDCHMDMmoDCHMDM
NegaBCGM. bovisH37RvbNegaBCGM. bovisH37RvbNegaBCGM. bovisH37RvbNegaBCGM. bovisH37Rvb
LILRA2111112121111121266666666
LILRB1111112121111121266666666
LILRB43344334433333333
LILRB26677667755555555
LILRB3111112121111121266666666
LILRA36677667755555555
LILRA46677667755555555
LILRA63344334433333333
LILRA53344334433333333
LILRA13344334433333333
LILRB53344334433333333

aNeg refers to untreated cells.

bH37Rv refers to M. tb strain H37Rv.

Determining mycobacterial binding to reporter cells expressing LILR

A cellular reporter system to assess LILR binding was generated as follows: The extracellular region of each LILR was amplified from previously cloned sequences. Each LILR PCR product was fused at the 5′ to an haemagglutinin A (HA) epitope preceded by the murine Ig k-chain leader sequence, and at the 3′ to the transmembrane domain of human platelet-derived growth factor receptor (PDGFR). These HA-tagged, LILR-PDGFR transmembrane constructs were cloned into the vector pMx puro which encoded the sequence of the cytoplasmic tail of the human CD3ζ chain (a gift from Dr Alex Barrow, St Louis USA)54] using the primers NK1313 (ATGCTTAATTAATCCACCATGGAGACAGAC) and NK1314 (CTTCTCGAGCCAAAGCATGATGAGGATG). Following transient transfection of PLAT-E retroviral packaging cells with the pMx HA-LILR-PDGFR-CD3ζ fusion constructs, recombinant retrovirus was used to transduce 2B4 T cell hybridoma cells that had previously been stably transfected with a NFAT-GFP reporter construct (a kind gift from Lewis Lanier, UCSF, San Francisco, California, USA)55. Hereafter these cells are referred to as 2B4 reporter cells. Following transduction, 2B4 reporter cells were sorted using a MoFlo cytometer (Beckman Coulter, Brea, CA, USA) for similar levels of expression of each LILR based on the level of expression of the LILR-fused N terminal HA epitope stained with an anti-HA-PE monoclonal antibody (Miltenyi Biotec, Bergisch Gladbach, Germany). 2B4 reporter cells were cultured at 105 in 200 μl RPMI (10% FCS, 1% P/S, and 2.5 μg/ml amphotericin B (PAA (Now GE Healthcare, USA)) per well of a 96 U-bottom plate. Mycobacteria were grown to exponential stage, and heat killed at 90 °C for 45 minutes. A separate experiment was performed with live BCG. Mycobacteria were added to each well at an MOI of 10:1 (Mycobacteria:cells) and incubated overnight at 37 °C, 5% CO2. The plates were then spun at 1000 rpm for one minute and the GFP level was then measured on FACScan using Weasel v2.0 software. Controls consisted of anti-HA monoclonal antibody (Miltenyi, UK) together with goat anti-mouse IgG (Fc) (ThermoScientific, UK) and cell culture only. The data was analysed using FlowJo VX.

Whole blood flow cytometry

Whole blood samples for flow cytometric analysis were prepared by adding the appropriate antibodies to 100 μl of whole blood, or 200 μl if diluted 1:2 with RPMI (table 2). Isotype control staining was performed for each patient and each analysis panel. Red blood cells were lysed and samples fixed using 500 μl of BD FACS lysing Solution (Becton Dickinson, UK) and incubated for up to 20 minutes. Each sample was then analysed on a BD LSR II Flow Cytometer with FACS Diva software (Becton Dickinson, UK).
Table 2

Antibodies used in all experiments.

SpecificityConjugateCatalogue No.Supplier
LIN 1FITC340546BD
HLA-DRPE-TRVXMHLDR17Invitrogen
CD11cPE-Cy7561356BD Pharmingen
CD123PE-Cy5561009BD
CD14PE-TRMHCD1417Invitrogen
CD16Pe-Cy7557744BD Pharmingen
CD3APC-H7641397BD Bioscience
CD4AF700560836BD Pharmingen
CD8AF700557945BD Pharmingen
γδ TCRFITC561995BD Pharmingen
CD56PE-TRVXMHCD5617Invitrogen
LILRB5/LIR8PurifiedMAB3065R&D
Anti-mouse IgGAPC17-4012-82Ebioscience
Anti-HAPE130-092-257Miltenyi
Anti-Mouse IgGPE31861Thermo
Mouse IgG2bFITC11-4732-41Ebioscience
Mouse IgG1APC550854BD
Mouse IgG1, κAPC-H7561427BD
Mouse IgG2aPE-Cy7552868BD
Mouse IgG2aPE-TRMG2a17Invitrogen

Gating immune cell subsets for analysis

DC populations were identified by selecting the HLA-DRHi (PE texas red) (Invitrogen, UK) positive and Lin− 1 (FITC) (Becton Dickinson, UK) negative population. Within the gated DC population, CD123+ (PE Cy5) (Becton Dickinson, UK) staining identified plasmacytoid DC (pDC) and CD11c+ (PE Cy7) (BD Pharmingen, UK) identified myeloid DC (mDC). The monocyte population was identified using forward and side scatter characteristics and individual monocytic subsets were identified by selecting populations based on the intensity of CD16 (PE Cy7) (BD Pharmingen, UK) and CD14 (PE texas red) (Invitrogen, UK) staining, which allowed for the identification of classical, intermediate, and non-classical populations. Lymphocyte populations were identified using forward and side scatter characteristics and T cell populations were identified by using anti-CD3 (APC-H7) (BD Bioscience), anti-CD4 (AF700) (BD Pharmingen, UK), anti-CD8 (PerCP) (BD Bioscience) and anti-γδ TCR (FITC) (BD Pharmingen, UK). Anti-CD3 antibody was plotted against anti-CD56 (PE texas red) (Invitrogen, UK) to distinguish NK cells and NKT cells. Surface expression of LILRB5 was determined for each subset using an anti-LILRB5 primary antibody (R&D) and Anti-Mouse IgG APC (eBioscience, UK) secondary antibody.

Mixed Lymphocyte Reactions

Peripheral blood mononuclear cells were separated from whole blood using density centrifugation over Ficoll-paque. T cell populations were purified from non-adherent cells using a CD4 MicroBeads Kit (Miltenyi, UK) or CD8 Microbeads Kit (Miltenyi, UK) following the manufacturer’s standard protocol. LILRB5 crosslinking of APC or T cells was performed using LILRB5 antibody (R&D) crosslinked with anti-mouse IgG. Negative controls were treated with anti-mouse IgG alone, or untreated cells. Allogeneic T cells were stained using a Cell Trace Violet Proliferation Kit (Life Technologies, UK), following the manufacturer’s standard protocol, then cultured with donor APC in RPMI1640 containing 1% Penicillin/Streptomycin for four days. Proliferation was determined using flow cytometric analysis on a BD LSR II Flow Cytometer with FACS Diva software. Analysis was completed using FlowJo VX, by gating around the T cell population identified by forward and side scatter characteristics, and then the enumeration of T cells stained with Cell Trace Violet was determined.

Statistical Analysis

All statistical analyses were performed using SPSS 20 and GraphPad Prism 6.05, based on the median values for all data. Non-parametric tests were used for mRNA expression analysis, with Mann-Whitney U-test used to determine significance between unpaired groups. Parametric two-tailed T-Test was used for paired samples in the mixed lymphocyte reaction. All p-values were corrected for ties, and values below 0.05 were considered significant.

Additional Information

How to cite this article: Hogan, L. E. et al. Expression of the innate immune receptor LILRB5 on monocytes is associated with mycobacteria exposure. Sci. Rep. 6, 21780; doi: 10.1038/srep21780 (2016).
  54 in total

1.  Alternative mRNA splicing creates transcripts encoding soluble proteins from most LILR genes.

Authors:  Des C Jones; Ali Roghanian; Damien P Brown; Chiwen Chang; Rachel L Allen; John Trowsdale; Neil T Young
Journal:  Eur J Immunol       Date:  2009-11       Impact factor: 5.532

Review 2.  Modulation of immune responses through direct activation of Toll-like receptors to T cells.

Authors:  G Liu; L Zhang; Y Zhao
Journal:  Clin Exp Immunol       Date:  2010-01-29       Impact factor: 4.330

3.  Increased frequency of ILT2-expressing CD56(dim)CD16(+) NK cells correlates with disease severity of pulmonary tuberculosis.

Authors:  Xinjing Wang; Xianghong Meng; Yue Zheng; Jing Jiang; Bingfen Yang; Yanhua Liu; Fei Zhai; Xiaoxing Cheng
Journal:  Tuberculosis (Edinb)       Date:  2014-05-14       Impact factor: 3.131

4.  Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers.

Authors:  Jinghe Huang; Patrick S Burke; Thai Duong Hong Cung; Florencia Pereyra; Ildiko Toth; Bruce D Walker; Luis Borges; Mathias Lichterfeld; Xu G Yu
Journal:  J Virol       Date:  2010-07-14       Impact factor: 5.103

5.  Leukocyte Ig-like receptor B4 (LILRB4) is a potent inhibitor of FcgammaRI-mediated monocyte activation via dephosphorylation of multiple kinases.

Authors:  Hao Kim Lu; Carles Rentero; Mark J Raftery; Luis Borges; Katherine Bryant; Nicodemus Tedla
Journal:  J Biol Chem       Date:  2009-10-15       Impact factor: 5.157

Review 6.  Modulation of Toll-like receptor activity by leukocyte Ig-like receptors and their effects during bacterial infection.

Authors:  Louise E Pilsbury; Rachel L Allen; Martin Vordermeier
Journal:  Mediators Inflamm       Date:  2010-06-20       Impact factor: 4.711

Review 7.  Immunoglobulin-like transcript 3: A crucial regulator of dendritic cell function.

Authors:  George Vlad; Chih-Chao Chang; Adriana I Colovai; Pasquale Berloco; Raffaello Cortesini; Nicole Suciu-Foca
Journal:  Hum Immunol       Date:  2009-03-09       Impact factor: 2.850

8.  PIR-B-deficient mice are susceptible to Salmonella infection.

Authors:  Ikuko Torii; Satoshi Oka; Muneki Hotomi; William H Benjamin; Toshiyuki Takai; John F Kearney; David E Briles; Hiromi Kubagawa
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

9.  The inhibitory receptor LILRB4 (ILT3) modulates antigen presenting cell phenotype and, along with LILRB2 (ILT4), is upregulated in response to Salmonella infection.

Authors:  Damien P Brown; Des C Jones; Katie J Anderson; Nicolas Lapaque; Robin A Buerki; John Trowsdale; Rachel L Allen
Journal:  BMC Immunol       Date:  2009-10-27       Impact factor: 3.615

10.  HLA-B*35-Px-mediated acceleration of HIV-1 infection by increased inhibitory immunoregulatory impulses.

Authors:  Jinghe Huang; James J Goedert; Eric J Sundberg; Thai Duong Hong Cung; Patrick S Burke; Maureen P Martin; Liliana Preiss; Jeffrey Lifson; Mathias Lichterfeld; Mary Carrington; Xu G Yu
Journal:  J Exp Med       Date:  2009-12-14       Impact factor: 14.307

View more
  12 in total

Review 1.  HLA associations in inflammatory arthritis: emerging mechanisms and clinical implications.

Authors:  Robert Busch; Simon Kollnberger; Elizabeth D Mellins
Journal:  Nat Rev Rheumatol       Date:  2019-06       Impact factor: 20.543

Review 2.  Leukocyte Immunoglobulin-Like Receptors (LILRs) on Human Neutrophils: Modulators of Infection and Immunity.

Authors:  Alexander L Lewis Marffy; Alex J McCarthy
Journal:  Front Immunol       Date:  2020-05-13       Impact factor: 7.561

3.  A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling.

Authors:  Junbin Qian; Siel Olbrecht; Bram Boeckx; Hanne Vos; Damya Laoui; Emre Etlioglu; Els Wauters; Valentina Pomella; Sara Verbandt; Pieter Busschaert; Ayse Bassez; Amelie Franken; Marlies Vanden Bempt; Jieyi Xiong; Birgit Weynand; Yannick van Herck; Asier Antoranz; Francesca Maria Bosisio; Bernard Thienpont; Giuseppe Floris; Ignace Vergote; Ann Smeets; Sabine Tejpar; Diether Lambrechts
Journal:  Cell Res       Date:  2020-06-19       Impact factor: 25.617

Review 4.  Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer.

Authors:  Mi Deng; Heyu Chen; Xiaoye Liu; Ryan Huang; Yubo He; Byounggyu Yoo; Jingjing Xie; Samuel John; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  Antib Ther       Date:  2021-02-09

Review 5.  Leukocyte Immunoglobulin-Like Receptors in Regulating the Immune Response in Infectious Diseases: A Window of Opportunity to Pathogen Persistence and a Sound Target in Therapeutics.

Authors:  Florence Abdallah; Sixtine Coindre; Margaux Gardet; Florian Meurisse; Abderrahim Naji; Narufumi Suganuma; Laurent Abi-Rached; Olivier Lambotte; Benoit Favier
Journal:  Front Immunol       Date:  2021-09-14       Impact factor: 7.561

Review 6.  The Genomic Organization of the LILR Region Remained Largely Conserved Throughout Primate Evolution: Implications for Health And Disease.

Authors:  Lisanne Storm; Jesse Bruijnesteijn; Natasja G de Groot; Ronald E Bontrop
Journal:  Front Immunol       Date:  2021-10-19       Impact factor: 7.561

Review 7.  Human inhibitory leukocyte Ig-like receptors: from immunotolerance to immunotherapy.

Authors:  Calvin D De Louche; Ali Roghanian
Journal:  JCI Insight       Date:  2022-01-25

8.  Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection.

Authors:  Narjes Saheb Sharif-Askari; Fatemeh Saheb Sharif-Askari; Bushra Mdkhana; Saba Al Heialy; Habiba S Alsafar; Rifat Hamoudi; Qutayba Hamid; Rabih Halwani
Journal:  Mol Ther Methods Clin Dev       Date:  2020-11-12       Impact factor: 6.698

9.  LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.

Authors:  Muchaala Yeboah; Charys Papagregoriou; Des C Jones; H T Claude Chan; Guangan Hu; Justine S McPartlan; Torbjörn Schiött; Ulrika Mattson; C Ian Mockridge; Ulla-Carin Tornberg; Björn Hambe; Anne Ljungars; Mikael Mattsson; Ivo Tews; Martin J Glennie; Stephen M Thirdborough; John Trowsdale; Björn Frendeus; Jianzhu Chen; Mark S Cragg; Ali Roghanian
Journal:  JCI Insight       Date:  2020-09-01

10.  Characterization and functional analyses of novel chicken leukocyte immunoglobulin-like receptor subfamily B members 4 and 5.

Authors:  Anh Duc Truong; Yeojin Hong; Ha Thi Thanh Tran; Hoang Vu Dang; Viet Khong Nguyen; Thu Thao Pham; Hyun S Lillehoj; Yeong Ho Hong
Journal:  Poult Sci       Date:  2019-12-01       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.